These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
213 related items for PubMed ID: 22040825
1. [Frontiers in vitamin D; basic research and clinical application. Inhibitory effects of eldecalcitol, an active vitamin D derivative, on bone resorption in vivo]. Harada S, Mizoguchi T, Takahashi N. Clin Calcium; 2011 Nov; 21(11):91-8. PubMed ID: 22040825 [Abstract] [Full Text] [Related]
2. Daily administration of eldecalcitol (ED-71), an active vitamin D analog, increases bone mineral density by suppressing RANKL expression in mouse trabecular bone. Harada S, Mizoguchi T, Kobayashi Y, Nakamichi Y, Takeda S, Sakai S, Takahashi F, Saito H, Yasuda H, Udagawa N, Suda T, Takahashi N. J Bone Miner Res; 2012 Feb; 27(2):461-73. PubMed ID: 22052469 [Abstract] [Full Text] [Related]
3. [Frontiers in vitamin D; basic research and clinical application. Eldecalcitol: the effect on bones and calcium metabolism]. Endo I, Matsumoto T. Clin Calcium; 2011 Nov; 21(11):103-10. PubMed ID: 22040826 [Abstract] [Full Text] [Related]
4. Mechanism of inhibitory action of eldecalcitol, an active vitamin D analog, on bone resorption in vivo. Takahashi N. J Steroid Biochem Mol Biol; 2013 Jul; 136():171-4. PubMed ID: 23220095 [Abstract] [Full Text] [Related]
5. [Current Topics on Vitamin D. Treatment of osteoporosis with eldecalcitol: Its therapeutic efficacy and adverse effect on renal function]. Takeuchi Y. Clin Calcium; 2015 Mar; 25(3):425-32. PubMed ID: 25716816 [Abstract] [Full Text] [Related]
6. Eldecalcitol and calcitriol stimulates 'bone minimodeling,' focal bone formation without prior bone resorption, in rat trabecular bone. Saito H, Takeda S, Amizuka N. J Steroid Biochem Mol Biol; 2013 Jul; 136():178-82. PubMed ID: 23069645 [Abstract] [Full Text] [Related]
7. Eldecalcitol: newly developed active vitamin D(3) analog for the treatment of osteoporosis. Hagino H. Expert Opin Pharmacother; 2013 Apr; 14(6):817-25. PubMed ID: 23477453 [Abstract] [Full Text] [Related]
8. [Frontiers in vitamin D; basic research and clinical application. A review on histological findings in bones administered with eldecalcitol]. Hongo H, Sasaki M, Hasegawa T, Amizuka N. Clin Calcium; 2011 Nov; 21(11):63-70. PubMed ID: 22040822 [Abstract] [Full Text] [Related]
9. Eldecalcitol for the treatment of osteoporosis. Matsumoto T, Endo I. Drugs Today (Barc); 2012 Mar; 48(3):189-96. PubMed ID: 22462038 [Abstract] [Full Text] [Related]
10. [Frontiers in vitamin D; Basic research and clinical application. The effects of eldecalcitol on bone mineral density and fracture prevention--Post hoc analysis]. Hagino H. Clin Calcium; 2011 Nov; 21(11):111-8. PubMed ID: 22040827 [Abstract] [Full Text] [Related]
11. Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation. Jiang Y, Tang H, Ma X, Cheng Q, Lin H, Jin X, Zhang Z, Yu W, He S, Kobayashi T, Uehara S, Matsumoto T, Xia W. J Bone Miner Metab; 2019 Nov; 37(6):1036-1047. PubMed ID: 31087185 [Abstract] [Full Text] [Related]
12. Treatment with the combination of ibandronate plus eldecalcitol has a synergistic effect on inhibition of bone resorption without suppressing bone formation in ovariectomized rats. Sakai S, Takeda S, Sugimoto M, Shimizu M, Shimonaka Y, Yogo K, Hashimoto J, Bauss F, Endo K. Bone; 2015 Dec; 81():449-458. PubMed ID: 26281770 [Abstract] [Full Text] [Related]
13. [Frontiers in vitamin D; Basic research and clinical application. Effect of eldecalcitol on bone structure]. Ito M. Clin Calcium; 2011 Nov; 21(11):119-25. PubMed ID: 22040828 [Abstract] [Full Text] [Related]
14. Multifunctional and potent roles of the 3-hydroxypropoxy group provide eldecalcitol's benefit in osteoporosis treatment. Ono Y. J Steroid Biochem Mol Biol; 2014 Jan; 139():88-97. PubMed ID: 24139874 [Abstract] [Full Text] [Related]
15. Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats. Hasegawa T, Yamamoto T, Sakai S, Miyamoto Y, Hongo H, Qiu Z, Abe M, Takeda S, Oda K, de Freitas PHL, Li M, Endo K, Amizuka N. J Histochem Cytochem; 2019 Mar; 67(3):169-184. PubMed ID: 30311820 [Abstract] [Full Text] [Related]
16. [Recent progress and problem of treatment with active vitamin D]. Fukumoto S. Clin Calcium; 2014 Jan; 24(1):53-8. PubMed ID: 24369280 [Abstract] [Full Text] [Related]
17. Eldecalcitol: a review of its use in the treatment of osteoporosis. Sanford M, McCormack PL. Drugs; 2011 Sep 10; 71(13):1755-70. PubMed ID: 21902297 [Abstract] [Full Text] [Related]
18. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA). Matsumoto T, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Nakano T, Ito M, Tomomitsu T, Hirakawa A, Soen S. J Bone Miner Metab; 2020 Jul 10; 38(4):522-532. PubMed ID: 32140784 [Abstract] [Full Text] [Related]
19. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment. Iba K, Sonoda T, Takada J, Dohke T, Yamashita T. J Bone Miner Metab; 2017 Mar 10; 35(2):171-176. PubMed ID: 26832388 [Abstract] [Full Text] [Related]
20. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol. Nakatoh S. J Bone Miner Metab; 2018 Mar 10; 36(2):221-228. PubMed ID: 28293779 [Abstract] [Full Text] [Related] Page: [Next] [New Search]